Daniel Camardo
Daniel is currently President Immedica North America, a subsidiary of Immedica Pharma AB, a global pharmaceutical company focused on the commercialization of medicines for rare disease and specialty care. Prior to joining Immedica, Daniel was Principal of CLC Biopharma, LLC providing consulting services to clinical stage biotech and specialty pharmaceutical companies. Prior to forming CLC Biopharma in 2024, Daniel was acting CEO and Board Director of Athersys, Inc., a publicly traded development stage biotech company advancing MultiStem, a proprietary allogeneic cell therapy as a single-dose treatment option for ischemic stroke, acute respiratory distress syndrome and trauma.
Prior to joining Athersys in 2022, Daniel was Executive Vice President and President U.S. of Horizon Therapeutics, a biotechnology company focused on serious, rare autoimmune and inflammatory diseases. Daniel was responsible for a diverse portfolio of specialty, rare and ultra-rare disease products generating over $3B in annual net sales. Prior to joining Horizon in 2015, Daniel spent 11 years helping build a successful U.S. enterprise for Astellas, a global pharmaceutical company based in Tokyo, Japan.
Over his career, Daniel has contributed to multiple blockbuster products (>$1B annual revenue) and successfully launched BLAs and NDAs in Oncology, Neurology, Immunology, Dermatology, Cardiology, Rheumatology, and Orphan/Rare Diseases. Daniel is passionate about bringing innovative biopharmaceutical solutions to market, helping patients who suffer from difficult to treat diseases and addressing complex marketplace challenges.
Daniel is a member of the Board of Directors of CommunityHealth, one of the largest volunteer-based health centers in the nation providing healthcare to low income, uninsured and underinsured patients in Chicago. Daniel also serves on the CommunityHealth Development and Finance Committees.
Daniel graduated from the University of Rochester with a B.A. degree in Economics and a minor in Mathematics and later completed his MBA from Kellogg School of Management (Northwestern University). In 2022, Daniel joined the Healthcare Program at the Kellogg School of Management (HCAK), where he teaches a course on Pharmaceutical Strategy.
Daniel lives in the north suburbs of Chicago with his wife and four children.
Pharmaceutical Strategy (HCAK-931-0)
The healthcare industry is not only highly regulated but also has multiple stakeholders. From policymakers such as FDA to payers, from providers to insurers, from physician researchers to patient advocacy groups, there is a rich variety of partners that calls for collaborative approaches and behaviors. This means that pharmaceutical leaders must not only acquire drug development expertise, but also become highly skilled in navigating the regulatory framework and managing multi-stakeholder networks. This course will provide contextual guidance and help leaders broaden their personal repertoire and toolbox to succeed with developing a comprehensive pharmaceutical strategy. The objective of this Pharmaceutical Strategy course is to build on the existing Healthcare Strategy to equip participants with a deep knowledge around drug commercialization so they can thrive in what is a hyper-complex healthcare, scientific and socioeconomic environment. A basic understanding of the health care industry is suggested but not required. Please note: STRT-443 Healthcare Strategy OR STRT-444 Healthcare Economics are STRONGLY recommended prerequisites for the class .
